TABLE OF CONTENTS

Faculty ix
Preface xi

I EPIDEMIOLOGY, THERAPEUTIC ENDPOINTS

1. The public health and clinical implications of the national increase in congestive heart failure 3
   Salim Yusuf, Thomas Thom, Jeffrey Probstfield
2. Therapeutic endpoints in the treatment of congestive heart failure with systolic dysfunction 9
   E.H. Sonnenblick and T.H. Lejemtel
3. Evaluation of ventricular function in patients with heart failure: invasive or noninvasive? 17
   Bertram Pitt
4. Assessment of neurohormonal parameters in congestive heart failure: determination of sodium and water regulation 25
   R.J. Cody
5. The assessment of quality of life and exercise response in patients with chronic cardiac failure 39
   Mariell Jessup

Panel Discussion 50

II PRECLINICAL ISSUES AND PROARRHYTHMIA DEFINITIONS

6. Animal models of heart failure 71
   Stewart J. Ehrreich
7. Electrophysiology in congestive heart failure animal models 97
   C. William Balke, Joseph F. Spear, E. Neil Moore

8. Noninvasive evaluation of proarrhythmia 105
J. Morganroth

9. Criteria for proarrhythmia in patients with congestive heart failure: use of electrophysiologic testing 117
Leonard N. Horowitz

Panel Discussion 131

III FDA ENDPOINT ISSUES

10. Are placebo-controlled trials necessary in the evaluation of new therapeutic agents in severe chronic heart failure? 143
Milton Packer

11. What the FDA requires for endpoint measures in congestive heart failure studies 151
Raymond J. Lipicky

12. Design of trials to assess safety and effectiveness in Rx of CHF 155
Robert Temple

Panel Discussion 171

IV THERAPEUTIC STRATEGIES

13. How does congestive heart failure alter response to drugs? 177
Dan M. Roden

14 Status of vasodilators for heart failure 187
Jay N. Cohn

15. Perspectives on the use of new phosphodiesterase inhibitors in the treatment of chronic cardiac failure 193
Thierry H. Lejemtel, Stuart Katz, Gad Keren, Edmund H. Sonnenblick

16. Is there a role for beta-blockers in heart failure patients? 211
Jeffrey L. Anderson

Panel Discussion 233

V CLINICAL TRIAL ISSUES

17. What CHF trials have shown to date and what is needed? 251
C. Furberg

18. How to study sudden cardiac death as an endpoint in congestive heart failure trials 255
J. Thomas Bigger, Jr.

19. Interpretation of clinical trials in patients with congestive heart failure 263
Lloyd D. Fisher

Panel Discussion 269

PARTICIPANTS 279